BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's ...

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The ...

HATFIELD, HERTFORDSHIRE, UNITED KINGDOM (UK), and MAIDENHEAD, UK, 7 JULY 2025 – Eisai Europe Ltd. and Biogen Idec Ltd. announced today that the Scottish Medicines Consortium (SMC) has not recommended ...

Because Alzheimer’s is just one of several diseases that cause dementia, the key distinction lies in their scope.

A recent study of patients who developed bipolar disorder or depression later in life revealed that half had high ...

They slow progression of the disease, but they can have serious side-effects. – What are the medicines? Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer ...

Japanese authorities are putting Eisai (TYO: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...

Drugs that slow progression of Alzheimer’s don’t provide enough benefit to justify substantial cost for NHS, regulator has said ...

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

The initiative follows the NHS spending watchdog's decision to turn down the use of novel Alzheimer's drugs lecanemab and donanemab for widespread NHS application. Despite receiving approval from the ...

After presentations to the International Linked Clinical Trials (iLCT), which was set up by Cure Parkinson’s over a decade ago, experts from both fields will select the most promising drugs for both ...